EQT Life Sciences’ Health Economics 3 Fund
Summary
The British Business Bank (BBB) has announced a significant commitment of £21.26 million (€25 million) to EQT Life Sciences’ Health Economics 3 Fund (EQT HE3). This investment is designed to foster innovation within Europe and enhance capital flow into the burgeoning UK life sciences sector, supporting the growth of medical technology and digital health companies.
Summary of transaction details:
- Value: £21.26 million (€25 million)
- Sector: Healthcare & Biotech (Medtech, Diagnostics, Digital Health)
- Advisor: Not disclosed
- Key Entities: British Business Bank (Investor), EQT Life Sciences’ Health Economics 3 Fund (Target)
- Location: UK (beneficiary of investment focus)
Note: This strategic fund commitment by the British Business Bank aims to support commercial-stage, de-risked companies that can improve patient care while simultaneously reducing healthcare costs, aligning with the UK's industrial growth strategy.
Lead Investor / Acquirer
British Business Bank
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series A prioritisedMore from British Business Bank
VC Funding
Series BKraken Technologies
£25,000,000
Healthcare & Biotech
VC Funding
Series AEpisode 1
£35,000,000
DeepTech & AI / Tech Bio / Software Infrastructure
VC Funding
Series CSeraphim Space (latest fund)
£74,000,000
Software/SaaS
VC Funding
GrowthApposite Healthcare Growth I
£100,000,000
Healthcare & Biotech
Original Source
View the original press release or news article describing this transaction in full.
Read Original PostAI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in